Brokers Issue Forecasts for Fractyl Health Q1 Earnings

Fractyl Health, Inc. (NASDAQ:GUTS) – Equities researchers at HC Wainwright issued their Q1 2026 earnings per share estimates for shares of Fractyl Health in a research note issued to investors on Wednesday, March 25th. HC Wainwright analyst J. Pantginis forecasts that the company will post earnings per share of ($0.14) for the quarter. HC Wainwright currently has a “Buy” rating and a $8.00 price objective on the stock. The consensus estimate for Fractyl Health’s current full-year earnings is ($1.61) per share. HC Wainwright also issued estimates for Fractyl Health’s Q2 2026 earnings at ($0.14) EPS, Q3 2026 earnings at ($0.15) EPS, Q4 2026 earnings at ($0.16) EPS, FY2026 earnings at ($0.59) EPS, FY2027 earnings at ($0.37) EPS and FY2028 earnings at $0.02 EPS.

Several other brokerages also recently commented on GUTS. Canaccord Genuity Group reissued a “buy” rating and set a $8.00 target price on shares of Fractyl Health in a research note on Thursday. Morgan Stanley downgraded shares of Fractyl Health from an “overweight” rating to an “equal weight” rating and reduced their price target for the company from $8.00 to $2.00 in a research note on Thursday, January 29th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Fractyl Health in a report on Monday, December 29th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $5.40.

Fractyl Health Stock Performance

NASDAQ:GUTS opened at $0.47 on Friday. The stock’s 50-day simple moving average is $0.73 and its 200 day simple moving average is $1.28. The firm has a market capitalization of $75.07 million, a PE ratio of -0.26 and a beta of 1.51. The company has a quick ratio of 4.27, a current ratio of 4.78 and a debt-to-equity ratio of 3.23. Fractyl Health has a twelve month low of $0.38 and a twelve month high of $3.03.

Fractyl Health (NASDAQ:GUTS) last posted its quarterly earnings results on Tuesday, March 24th. The company reported $0.15 EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.34.

Hedge Funds Weigh In On Fractyl Health

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Rosalind Advisors Inc. bought a new position in shares of Fractyl Health during the third quarter valued at $7,950,000. Scientech Research LLC acquired a new stake in Fractyl Health in the third quarter valued at $49,000. Jane Street Group LLC acquired a new stake in Fractyl Health in the second quarter valued at $31,000. 683 Capital Management LLC raised its position in Fractyl Health by 30.1% during the 4th quarter. 683 Capital Management LLC now owns 6,047,620 shares of the company’s stock worth $13,305,000 after purchasing an additional 1,397,620 shares during the last quarter. Finally, Catalio Capital Management LP raised its position in Fractyl Health by 5.3% during the 4th quarter. Catalio Capital Management LP now owns 5,491,866 shares of the company’s stock worth $12,082,000 after purchasing an additional 277,630 shares during the last quarter.

More Fractyl Health News

Here are the key news stories impacting Fractyl Health this week:

• Positive Sentiment: HC Wainwright raised multiple multi‑year EPS forecasts (notably FY2026, FY2027, FY2028 and later years), reaffirmed a “Buy” rating and kept an $8.00 price target — the firm now models a path to profitability in later years, which supports upside vs. the current price. HC Wainwright research note (summary)
• Positive Sentiment: Canaccord Genuity reaffirmed its “buy” stance and a $8.00 price target, echoing bullish analyst sentiment and contributing to buying pressure. Canaccord coverage (Benzinga)
• Positive Sentiment: Media reported a notable after‑hours price surge (~21% after a recent catalyst), reflecting short‑term momentum driven by the analyst activity and investor reaction. MSN: GUTS stock jumps after hours
• Neutral Sentiment: Q4 2025 earnings call transcript is available for review (useful for details on revenue, clinical progress and management commentary). Investors should read the call for specifics behind the beats and forward commentary. Earnings call transcript
• Negative Sentiment: TipRanks flagged a new regulatory disclosure: Fractyl faces “significant compliance risks” under global anti‑corruption and sanctions laws. Such disclosures can increase legal/operational risk and weigh on sentiment if they lead to investigations or remediation costs. TipRanks: compliance risks

Fractyl Health Company Profile

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company’s lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.